Open in interactive viewer → charts, metric popovers & call review

Journey Medical Grew Everything But the Stock Price

Record Emrosi scripts, a second straight positive EBITDA quarter and a 25-million-life formulary win in hand — yet the shares are down 37% in 90 days. The market is reading the copay lever, not the script line.
DERM · Earnings Call · 2026-11-12

The quarter that should have been a victory lap

Journey Medical is a ~$122 million market-cap specialty pharma. It sells one thing that matters: Emrosi, an oral minocycline for rosacea it launched in April 2025 and which carried roughly half of the $19 million in Q3 revenue. On paper, the November 12 print was the best of the launch: revenue of $19 million versus $15 million a year ago, Emrosi at $9 million, prescriptions of ~40,000 up from ~36,000, unique prescribers through 5,000 (a full-year internal goal hit early), refill rates up nearly 12% sequentially, gross margin at 69%, and adjusted EBITDA of $3.5 million against $1.4 million. Management even reached profitability on a GAAP operating line. The tape says something else. “Net sales of Emrosi were $9 million in the third quarter, up year-over-year and sequentially from the second quarter, driven by higher prescription volume, improving payer reimbursement and an increase in the number of dermatology writers prescribing the brand.” — Claude Maraoui, Co-Founder, President and Chief Executive Officer · 2026-11-12 That is a clean operating story. The stock did not buy it: DERM fell 38% in seven weeks off a September 8 peak of $7.97, ended the 90-day window down 37%, and sits 46% below that high. For a micro-cap trading at 2.9x revenue, a 46% drawdown into an in-line quarter is the story to explain.

What actually changed: the copay lever, not the script line

The new information this quarter was not clinical. It was the mechanics of price. Emrosi's net revenue per prescription depends less on demand than on the mix between covered claims and Journey's copay bridging program — a subsidy for patients whose plan does not yet cover the drug. That lever got yanked around:

when we launched our program back in April of 2025, when we launched Emrosi, we actually started with a 0.50 copay program. And then a couple of months later, we switched over to 0.0. And then later on, another switch occurred back in January of this year to 0.35.

Claude Maraoui, Co-Founder, President and Chief Executive Officer · 2026-11-12
In Q3 they moved it back to $0.50 — to optimize profitability — and, predictably, script volume wobbled: “We talked a little bit about the volatility. We're seeing some good comeback right now.” — Claude Maraoui, Co-Founder, President and Chief Executive Officer · 2026-11-12 The company describes a four-to-eight-week air pocket and a December recovery. Analysts caught it: one noted third-party TRx running below the 3Q weekly average in October. This is a real tension, not a rounding error. Every flip of the copay dial mechanically moves both volume and the co pay line inside gross-to-net, and it makes revenue per script un-forecastable in the short run — a theme this management has been poked on for four straight calls. Back in March, an analyst flagged Q4 revenue per script at roughly $180 and Claude Maraoui pushed back: “That is not a good indicator in terms of our long-term net pricing.” — Claude Maraoui, Co-Founder, President and Chief Executive Officer · 2026-03-25 In August he was adamant ASPs only went up: “our expectation is that we will continue to gain better ASPs as more reimbursement from our payer strategy gets implemented.” — Claude Maraoui, Co-Founder, President and Chief Executive Officer · 2026-08-12 This quarter, the same expectation comes with a fresh qualifier about deductible resets — “some of that may take a little bit of time to really flow through to truly see the benefit.” — Ramsey Alloush, Chief Operating Officer and General Counsel · 2026-11-12 Directionally identical language, but the confidence has been softened three calls running.

The January catalyst is real, and it is slow

The strongest asset Journey owns right now is a formulary win it cannot yet book: a national plan covering over 25 million lives, effective January 2027. “we are expecting to be added to the -- it is the largest national plan in the United States. We expect that to go into effect at the beginning of the year, so 2027.” — Ramsey Alloush, Chief Operating Officer and General Counsel · 2026-11-12 That is the single most consequential sentence in the transcript, and it is forward-dated past two more reported quarters. The pace of that grind is the underrated detail. High-quality access — defined as a single-step edit or better — was described as ~34% of commercial lives in May, ~38% in August, and 40% now. Progress, but two points a quarter against a formulary coverage wall. The company is framing it as a quality coverage benchmark rather than raw lives, which is intellectually honest and strategically correct — but it also means the large national plan win is a step-change, not a trend. There is cross-sectional confirmation that this is the binding constraint for the whole small-cap specialty pharma cohort, not a Journey-specific stumble. In the same five-day reporting window, ACOG cited a formulary coverage gap, FENC touted a national formulary win, and PTHS leaned on formulary coverage to underwrite ZELSUVMI. Access is the moat; the molecule is table stakes. Journey's rosacea-specific spin — nearly 30% of mild-to-moderate patients reaching clear skin versus 12.8% on Oracea — is a genuine differentiator, and the pitch to be added to consensus treatment guidelines for rosacea would be a durable, non-price lever if it lands.

What went quiet

More telling than what management said is what it stopped saying. The base business — Qbrexza, Accutane, and the Urox anti-itch launch trained in June and shipped in July — was a pillar of the May and August Q&A. This quarter it barely appeared; the entire conversation was Emrosi. That is either ruthless focus or a signal that the non-Emrosi half of revenue is flat-to-declining and no longer worth narrating. Given Qbrexza had already been demoted to second position behind Emrosi, and Accutane has been fighting generics, focus is the charitable read. Guidance is the other silence. Asked directly about formal 2027 revenue or EBITDA guidance, Maraoui deferred again: “we're strongly considering it... we're probably going to be somewhat apprehensive here in the first half of next year to give any particular guidance.” — Claude Maraoui, Co-Founder, President and Chief Executive Officer · 2026-11-12 That is the third consecutive quarter of "in due time" on the same question — and it sits awkwardly next to the promise of a January formulary step-up. Similarly, the $1.7 million of SG&A was a one-time vendor settlement, explained by the CFO as “a dispute with a former vendor from several years ago. It's nonrecurring, onetime payment” — Joseph Benesch, Chief Financial Officer · 2026-11-12 — a genuine cash outlay, not an accrual release, which is why cash fell to $22.3 million from $24.1 million at year-end. And the balance sheet is the quiet risk. Effective net cash has gone from $48 million in 2021 to roughly zero, and free cash flow is still running around negative $3 million a quarter. Meanwhile R&D has fallen to roughly $54 thousand — down 94% year over year and effectively zero against $19 million of revenue. Emrosi's IP runs to 2039, so this is a rational harvest posture; it is also a company with no second act funded.

Bottom line

Journey is a commercial machine now performing well on every metric it controls — awareness of Emrosi, prescriber breadth, refill depth, margins — and badly on the one it does not: payer timing. The 46% drawdown is the market refusing to underwrite a January 2027 formulary event that management itself will not guide to. If the 25-million-life plan converts as expected and ASP inflects in the back half of 2027, this print will look like the bottom of a very loud air pocket. If it slips, the copay bridge is the only thing holding the volume line up, and a $122 million company with no cash cushion has very little room to maneuver.